Twice-yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...
Healio

Long-acting medications transform HIV prevention, treatment

Although HIV infection remains a global public health challenge, ART has transformed it from a fatal illness to a manageable lifetime condition for those who are successfully being treated.Initially, ...
Business Wire

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany, ...
Business Wire

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment ...